Brief Introduction

Shenzhen Chipscreen Biosciences Co., Ltd (Chipscreen Biosciences, Shanghai: 688321) was established in March 2001, and has currently become a leading enterprise in developing and manufacturing small molecule innovative medicines in China.

CHIPSCREEN BIOSCIENCES puts as the first priority to meet unmet clinical needs. It insists on “original, safe, excellent and effective China,” and is dedicated in providing patients with affordable innovative therapeutic drugs.

CHIPSCREEN BIOSCIENCES has utilized its proprietary chemical genomics-based discovery platform to successfully develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas.

CHIPSCREEN BIOSCIENCES has become a four-in-one modern biotech group company, which currently has headquarter / research and development center / GMP production base in Shenzhen, a regional headquarter / research and development center / GMP production base in Chengdu, as well as Beijing clinical research center and Shanghai commercial center.

Till now, the company has developed a number of original new drug pipelines for tumors, diabetes, and endocrine and autoimmune diseases.

Company Overview

Full name Shenzhen Chipscreen Biosciences Co., Ltd
Abbreviations Chipscreen Biosciences
Code 688321
Founded 20010321
Listing 20190812
Domicile Shenzhen
Website www.chipscreen.com
Email ir@chipscreen.com
STAR Theme Biological Medicine
CSRCSector Pharmaceutical Industry
Has weighted voting rights structure? No

Financials

Highlights

  2018 2017 2016
Earnings Per Share 0.09 0.07 0.02
R&D expenditure as a % of operating revenue 55.85% 62.01% 60.52%
Operating Revenue 147,688,982.21 110,503,440.20 85,364,443.64
Net Income 31,164,799.98 24,073,891.30 5,244,319.68

Income Statement (Unit: RMB mn)

  2018 2017 2016
Operating Revenue 147.69 110.50 85.36
Operating Costs 5.51 5.26 2.17
Operating Income 147.69 110.50 85.36
Pretax Income 32.17 23.66 5.24
Income Tax 100.20 -0.42 0
Net Income 31.16 24.07 5.24

Balance Sheet(Unit: RMB mn)

  2018 2017 2016
Assets
Current Assets-Total 233.47 310.82 226.05
Non-current Assets-Total 482.87 345.20 177.08
Total Assets 716.34 656.02 403.13
Liabilities
Current Liabilities-Total 81.53 76.72 111.56
Non-current Liabilities-Total 157.91 128.75 78.17
Total Liabilities 239.44 205.47 189.73
Stockholder's Equity
Share Capital 360.00 108.14 104.05
Retained Profits -39.02 -80.98 -105.05
Total Owners' Equity 476.90 450.56 213.40

Cash Flow Statement (Unit: RMB mn)

  2018 2017 2016
Net Cash Flows-Operating 22.78 2.73 59.77
Net Cash Flows-Investing -13.33 -196.09 -135.60
Net Cash Flows-Financing 17.95 192.21 141.60

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
博奥生物集团有限公司 42.92 10.4682%
萍乡永智英华元丰投资合伙企业(有限合伙) 28.32 6.9078%
LAV One (Hong Kong) Co., Limited 25.36 6.1864%
Vertex Technology Fund (Ⅲ) Ltd 23.85 5.8179%
深圳市海粤门生物科技开发有限公司 22.94 5.5941%
XIANPING LU 22.19 5.4110%
深圳海德睿博投资有限公司 19.82 4.8335%
深圳市圣明创业投资合伙企业(有限合伙) 16.79 4.0958%
深圳市海德康成投资合伙企业(有限合伙) 15.29 3.7281%
深圳市招银一号创新创业投资合伙企业(有限合伙) 12.55 3.0601%
 

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.